Understanding the Risks of Mounjaro on the NHS — and in Private Care

The side effects that most people encounter

The vast majority of reported side effects with tirzepatide sit in the digestive system. Nausea heads the list, followed by loose stools, constipation, vomiting, acid reflux and burping. Fatigue, headache and dizziness appear less often. Injection-site reactions (mild redness or discomfort at the site) are also common. These effects are not random: they tend to cluster around the early weeks of treatment and again after each dose step. For most people they settle within a few days to a couple of weeks as the body adjusts. Eating smaller portions, avoiding fatty or spicy food, and staying well hydrated all help. If side effects feel severe or are not improving, that is a conversation for your prescriber, not a reason to adjust the dose yourself. The full overview of how tirzepatide works explains why the gastrointestinal profile develops the way it does, slowing gastric emptying is central to how the medicine reduces appetite, and that same mechanism is behind the nausea.

Tirzepatide carries the Black Triangle symbol because it is still under additional post-authorisation monitoring by the MHRA. That does not mean it is more dangerous than older medicines; it means regulators are still building the real-world safety picture. You can contribute to that picture, and flag anything unexpected, through the Yellow Card reporting scheme.

When to get medical help without delay

A handful of symptoms require prompt attention rather than a "watch and wait" approach. Severe, persistent stomach pain that reaches into the back (with or without vomiting) should prompt urgent medical assessment because of the risk of pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically drawing attention to this pattern across GLP-1 medicines, including tirzepatide. It is uncommon, but the consequences of a delayed diagnosis are serious.

Other symptoms that warrant prompt contact with a healthcare professional include signs of an allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat), symptoms pointing to gallbladder problems (right-sided abdominal pain with fever or jaundice), and evidence of significant dehydration following severe vomiting or diarrhoea, prolonged fluid loss can affect kidney function. If you develop sudden changes in vision, tell your prescriber; this is particularly relevant if you have a background diagnosis of diabetic retinopathy. Low mood or any thoughts of self-harm should always be disclosed. A quick habit worth building: before each new pen, run through the Patient Information Leaflet's urgent-symptoms section, it takes under a minute and is specific to your dose. The FAQs section also covers common safety questions patients raise before and during treatment.

Who should not take tirzepatide, and what an NHS risk assessment looks like

Prescribing decisions under the NHS and privately both begin with the same clinical question: does this person's profile make tirzepatide appropriate? The contraindication list includes pregnancy and breastfeeding, active attempts to conceive, a personal or close family history of medullary thyroid carcinoma or MEN2, and a history of acute pancreatitis or serious gastrointestinal disease. Children and young people under 18 are outside the licensed indication entirely.

Women using oral contraceptives face a practical consideration specific to tirzepatide: absorption of the pill may be reduced during the first four weeks of treatment and for four weeks following each dose increase. UK guidance advises adding a barrier method during those windows. This differs from semaglutide, where the same concern has less evidence behind it. NHS England's weight-management injections guidance covers contraception and HRT considerations in detail. If you are weighing up how NHS eligibility criteria map onto your own health picture, the guide to Mounjaro on the NHS sets out the phased criteria clearly.

The risks of Mounjaro on the NHS or through a private regulated pharmacy are clinically identical, the medicine is the same. What varies is who reviews your history and how thoroughly. At nume, a GPhC-registered Independent Prescriber reads every consultation on the same day it is submitted; your eligibility and contraindications are assessed by a named clinician, not an automated filter. You can read more about our clinical team if you want to understand who would be reviewing your case.

Making the decision: private versus NHS, and the safety picture

The risks of tirzepatide do not change depending on which route you use to access it. What the route does affect is how quickly you get there, what monitoring is in place, and whether the medicine is genuine. The NHS phased rollout means many people currently meeting clinical criteria for tirzepatide face long waits or do not yet qualify under the current cohort thresholds; getting Mounjaro on the NHS involves meeting strict BMI and comorbidity criteria that are still being phased in. Private prescribing through a regulated pharmacy offers an alternative, but the same safety standards apply: prescription-only, clinician-reviewed, licensed UK supply chain.

If you are considering private treatment, it is reasonable to check any online pharmacy on the GPhC's public pharmacy register before proceeding. Counterfeit pens remain a live risk in the UK market; the MHRA has repeatedly warned against medicines sold online without a proper clinical assessment. Supply through a GPhC-registered pharmacy dispensing from the licensed UK chain removes that risk. Buying Mounjaro online safely means verifying the pharmacy first, not after. The cost of tirzepatide varies by provider and dose, and price alone is not a reliable indicator of legitimacy. If you are planning ahead with your supply, it is worth reading about whether you can buy more than one Mounjaro pen at a time before you place an order. Our prescribers discuss suitability and side effects as part of every consultation, speak to our prescribers to find out whether treatment is appropriate for you.